Foundation Medicine

Over 20 years of experience in biotech and diagnostic business development with a focus on negotiating and structuring complex revenue generating business development partnerships, in-licensing of high value technologies, and conducting due diligence for potential acquisition opportunities. An energetic business development executive with a drive for results, a consultative selling style and broad pharma knowledge and contacts. Additional roles have included leading marketing, strategic planning, corporate development, and scientific teams. Specialties: Companion Dx Deal Making, Strategic Planning, Licensing, M&A, Valuation, Financial Analysis and Modeling, Project Management, Business Development, Alliance Management,

Strategic commercial executive with expertise in product development, marketing, strategy, sales and commercial execution of global molecular diagnostic products in oncology and women’s health.

Strategic leader with a track record of building and growing exceptional recruiting teams. Recognized leadership excellence combined with hands-on capabilities to handle any step in the talent acquisition function. Deep experience working for and partnering with world class companies and delivering top talent to them at both executive and staff levels.

Member of original management team that grew NxStage from a pre-revenue startup company with 20 US employees to a public medical device and dialysis services business with over $400 million in annual worldwide revenues and over 5,000 employees. Developed eleven person legal department with nine attorneys (before Fresenius merger agreement) and two paralegals, manage investor relations function from 2007 to present, managed human resources from 2008 through 2013. Successfully led diligence and merger agreement negotiations that culminated in the signing in August 2017 of a $2 billion merger agreement with Fresenius Medical Care Holdings, Inc., pending FTC approval. Oversee all legal activities, including securities filings, corporate governance, M&A and business development, corporate and commercial transactions, compliance, intellectual property, litigation, and international work. Oversee prosecution and defense of a portfolio of intellectual property with over 250 US and OUS patents, oversee freedom to operate analysis for all products and products under development, successfully defended inter partes review as well as oppositions initiated by competitors in Europe. Serve as Chief Compliance Officer. Successfully managed and settled significant Lanham Act litigation, oversee all other litigation, including employment, OSHA and products liability matters. Provided legal support to regulatory and public policy efforts that led to benchmark FDA indication clearances (e.g., home, nocturnal and solo hemodialysis) and important CMS payment policy changes (e.g., articulation of payment methodology for more frequent hemodialysis and increased home training payment). Serve as NxStage's corporate representative on the Kidney Care Council.

With a competitive nature, an entrepreneurial drive, and strong business acumen, I have thrived in the BioPharma and Molecular Diagnostic marketplaces for over two decades. Extensive knowledge of the pharma, in-vitro DX, molecular oncology and consumer market space. I have built a reputation for driving sales and revenue growth by developing talented individuals and creating a “Winning” culture. I have transformed multiple under-performing teams into skilled revenue producers by enhancing business acumen and sales techniques through regular coaching and mentoring. In all circumstances, I am driven by helping others, whether that means developing teams or launching and selling products that improve patients’ health. I bring a collaborative, adaptable approach, high energy, and a positive attitude to every challenge I take on.

Healthcare and Life Science leader with a strong focus on finance and business performance and proven track record of leading change and transformation across functions, countries and cultures